

Antonio Scalfari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6107522/publications.pdf>

Version: 2024-02-01

25
papers

1,931
citations

687363

13
h-index

642732

23
g-index

26
all docs

26
docs citations

26
times ranked

2661
citing authors

#	ARTICLE	IF	CITATIONS
1	The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. <i>Brain</i> , 2010, 133, 1914-1929.	7.6	563
2	Abnormal associative plasticity of the human motor cortex in writer's cramp. <i>Brain</i> , 2003, 126, 2586-2596.	7.6	353
3	Onset of secondary progressive phase and long-term evolution of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 67-75.	1.9	224
4	Mortality in patients with multiple sclerosis. <i>Neurology</i> , 2013, 81, 184-192.	1.1	199
5	Clinical prognostic factors in multiple sclerosis: a natural history review. <i>Nature Reviews Neurology</i> , 2009, 5, 672-682.	10.1	138
6	Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 214.	9.0	88
7	The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. <i>Neurology</i> , 2018, 90, e2107-e2118.	1.1	82
8	Smouldering multiple sclerosis: the "real MS"™. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642110667.	3.5	72
9	Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2015, 10, e0135428.	2.5	49
10	The CSF Profile Linked to Cortical Damage Predicts Multiple Sclerosis Activity. <i>Annals of Neurology</i> , 2020, 88, 562-573.	5.3	46
11	Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1007-1013.	1.9	22
12	Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. <i>The Cochrane Library</i> , 2017, 4, CD012200.	2.8	20
13	Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e890-e901.	1.1	19
14	A novel prognostic score to assess the risk of progression in relapsing-remitting multiple sclerosis patients. <i>European Journal of Neurology</i> , 2021, 28, 2503-2512.	3.3	14
15	MS progression is predominantly driven by age-related mechanisms "YES. <i>Multiple Sclerosis Journal</i> , 2019, 25, 902-904.	3.0	11
16	Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients. <i>Current Opinion in Neurology</i> , 2021, 34, 277-285.	3.6	6
17	Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach: Measuring disability in relapsing-remitting MS. <i>Neurology</i> , 2011, 76, 1025-1026.	1.1	5
18	Prognostic information for people with MS: Impossible or inevitable?. <i>Multiple Sclerosis Journal</i> , 2020, 26, 771-773.	3.0	5

#	ARTICLE	IF	CITATIONS
19	Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110576.	3.5	5
20	Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1442-1450.	3.0	3
21	MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Yes. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1002-1004.	3.0	3
22	Combined MRI Lesions and Relapses as a Surrogate for Disability in MS. <i>Neurology</i> , 2012, 78, 1367-1367.	1.1	2
23	Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome – NO. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1371-1374.	3.0	2
24	Reply to Oluf Anderson's Reply: Predicting a window of therapeutic opportunity in multiple sclerosis. <i>Brain</i> , 2011, 134, e175-e175.	7.6	0
25	Monoclonal Antibody Therapy and Long-term Outcomes in Multiple Sclerosis – The Challenge of Treatment Optimisation. <i>European Neurological Review</i> , 2018, 13, 78.	0.5	0